Premium
Targeted immunomodulation using antigen‐conjugated nanoparticles
Author(s) -
McCarthy Derrick P.,
Hunter Zoe N.,
Chackerian Bryce,
Shea Lonnie D.,
Miller Stephen D.
Publication year - 2014
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.1263
Subject(s) - nanomedicine , immune system , drug delivery , nanotechnology , drug , targeted drug delivery , drug discovery , conjugated system , computational biology , medicine , immunology , biology , bioinformatics , nanoparticle , pharmacology , chemistry , materials science , organic chemistry , polymer
The growing prevalence of nanotechnology in the fields of biology, medicine, and the pharmaceutical industry is confounded by the relatively small amount of data on the impact of these materials on the immune system. In addition to concerns surrounding the potential toxicity of nanoparticle ( NP )‐based delivery systems, there is also a demand for a better understanding of the mechanisms governing interactions of NPs with the immune system. Nanoparticles can be tailored to suppress, enhance, or subvert recognition by the immune system. This ‘targeted immunomodulation’ can be achieved by delivery of unmodified particles, or by modifying particles to deliver drugs, proteins/peptides, or genes to a specific site. In order to elicit the desired, beneficial immune response, considerations should be made at every step of the design process: the NP platform itself, ligands, and other modifiers, the delivery route, and the immune cells that will encounter the conjugated NPs can all impact host immune responses. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease